Program
FB102
A development code. Also written as “FB102 Single dose - Part A”, “FB102 Multiple doses - Part B” and “FB102 Multiple doses - Part C”.
Its studies are mostly in Vitiligo · Alopecia Areata · Celiac Disease, led by argenx.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| argenx | 44 open or running | phase 2since May 13, 2025 | Mar 11, 2025 | Dec 31, 2026phase 1 · NCT06905873 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 11, 2025First study: phase 1 study in VitiligoFirst studyNCT06905873 · 64 enrolled · Australia, New Zealand
- May 13, 2025Phase 2 study in Celiac DiseaseNCT06982963 · 100 planned · Australia
- Sep 25, 2025Phase 1 study in Alopecia AreataNCT07205159 · 32 planned · Australia, New Zealand
- May 28, 2026Phase 1 study in Healthy VolunteerNCT07623057 · 64 planned · Australia
Ahead
- Dec 31, 2026Primary completion: phase 1 study in VitiligoNCT06905873
- Feb 2027Primary completion: phase 1 study in Healthy VolunteerNCT07623057
- Feb 28, 2027Primary completion: phase 2 study in Celiac DiseaseNCT06982963
- Mar 10, 2027Primary completion: phase 1 study in Alopecia AreataNCT07205159
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07623057Healthy Volunteer · Australia | 1 | Recruiting | Feb 2027 | 64 |
| NCT07205159Alopecia Areata · Australia, New Zealand | 1 | Recruiting | Mar 10, 2027 | 32 |
| NCT06982963Celiac Disease · Australia | 2 | Recruiting | Feb 28, 2027 | 100 |
| NCT06905873Vitiligo · Australia, New Zealand | 1 | Active, not recruiting | Dec 31, 2026 | 64 |
How it is read
Names in the registry
- “FB102”, 3 entries
- “FB102 Single dose - Part A”, 1 entry
- “FB102 Multiple doses - Part B”, 1 entry
- “FB102 Multiple doses - Part C”, 1 entry
Codes read as this program: FB102.
Conditions, from the studies’ own filings
- Vitiligo, 1 study
- Alopecia Areata, 1 study
- Celiac Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.